Question

Difficulty: HardHematology and Oncology

During morning rounds, a 5858-year-old male inpatient is evaluated on postoperative day 77 following an open partial gastrectomy for gastric adenocarcinoma. The patient reports new-onset severe right calf pain and swelling that began earlier this morning, along with mild shortness of breath. His medications include pantoprazole and subcutaneous unfractionated heparin, which was started postoperatively for venous thromboembolism prophylaxis. Temperature is 37.8∘C37.8^\circ \text{C} (100.0∘F100.0^\circ \text{F}), blood pressure is 135/85 mmHg135/85 \text{ mmHg}, pulse is 105/min105/\text{min}, and respirations are 18/min18/\text{min}. Pulse oximetry shows 96%96\% on room air. Physical examination reveals a swollen, erythematous, and tender right calf. Lungs are clear to auscultation bilaterally.

Complete laboratory panel shows:
Laboratory TestResult
Hemoglobin11.2 g/dL11.2 \text{ g/dL}
Leukocyte count8,500/μL8,500/\mu\text{L}
Platelet count105,000/μL105,000/\mu\text{L} (Baseline prior to surgery: 240,000/μL240,000/\mu\text{L})
Serum creatinine1.1 mg/dL1.1 \text{ mg/dL}
Prothrombin time12 seconds12 \text{ seconds}
Activated partial thromboplastin time32 seconds32 \text{ seconds}

Which of the following is the most appropriate next step in management?

  1. Discontinue unfractionated heparin and initiate argatrobanAnswer
  2. B
    Discontinue unfractionated heparin and initiate enoxaparin
  3. C
    Obtain a lower extremity venous duplex ultrasound and continue current medications
  4. D
    Administer a pool of donor platelets
  5. E
    Obtain blood cultures and initiate intravenous vancomycin and piperacillin-tazobactam

Answer

The correct answer is to discontinue unfractionated heparin and initiate a non-heparin anticoagulant such as argatroban.
This patient's clinical presentation is highly suspicious for type 2 Heparin-Induced Thrombocytopenia (HIT) complicated by a new deep vein thrombosis (DVT). The diagnosis of HIT is assessed using the '4 T's' score, which evaluates Timing (typically 55-1010 days after heparin exposure), Thrombocytopenia (a greater than 50%50\% drop from baseline), Thrombosis (new venous or arterial clots), and the absence of oTher causes. This patient meets the criteria for a high-probability score (day 77, >50%>50\% platelet drop, and a new DVT). The immediate, life-saving next step in management is to strictly discontinue all heparin exposure (including line flushes) and immediately initiate therapeutic anticoagulation with a non-heparin agent, such as a direct thrombin inhibitor (e.g., argatroban) or fondaparinux, to prevent further massive thrombosis.

Step-by-Step Solution

1
Calculate the patient's '4 T's' score for Heparin-Induced Thrombocytopenia (HIT).
The patient has appropriate Timing (day 7 of therapy), significant Thrombocytopenia (drop from 240,000 to 105,000, which is >50%), and a new Thrombosis (clinical symptoms of DVT), making HIT highly probable.
Recognizing the clinical triad of heparin exposure, platelet drop, and new thrombosis is required to correctly diagnose HIT.
2
Determine the immediate management for high-probability HIT.
All heparin products must be stopped immediately. Waiting for confirmatory laboratory testing (e.g., serotonin release assay) is inappropriate.
Continued exposure to heparin will worsen the hypercoagulable state and lead to severe complications like pulmonary embolism or limb ischemia.
3
Select the appropriate alternative therapy.
Therapeutic anticoagulation with a non-heparin agent (e.g., direct thrombin inhibitors like argatroban or bivalirudin, or fondaparinux) must be initiated.
Anticoagulation is required because HIT is a highly prothrombotic state. Low-molecular-weight heparins (like enoxaparin) cannot be used due to cross-reactivity.

Key Concept

Diagnosis and acute management of Heparin-Induced Thrombocytopenia (HIT)
Rate this question